Tagged: psma
4 results
Indi Molecular
Indi Molecular is a Culver City, California biotech developing a synthetic alternative to antibodies called Protein Catalyzed Capture (PCC) agents - small, stable cyclic peptides built with click chemistry that bind protein targets with antibody-like specificity while behaving like small-molecule drugs. Spun out of Caltech chemist James Heath's lab in 2013, the company applies its platform to targeted oncology therapeutics and PET imaging agents, aiming to reach targets long considered undruggable, including KRAS G12D pancreatic cancer and ovarian cancer.
Philina Lee
Philina Lee, PhD is the Chief Executive Officer of AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer built on a proprietary Lead-212 platform. A biopharmaceutical executive with more than two decades in oncology, she was Chief Commercial Officer at Blueprint Medicines (acquired by Sanofi for roughly $9.5 billion) and earlier helped build the organization at Algeta that launched Xofigo, the first approved alpha therapy. Trained as a cell biologist at MIT, she took the AdvanCell helm on January 1, 2026 to lead the company's US expansion from a new Boston-area headquarters and advance its lead candidate 212Pb-ADVC001 for prostate cancer.
Convergent Therapeutics, Inc.
Convergent Therapeutics is a clinical-stage biotechnology company in Cambridge, Massachusetts developing next-generation targeted radiotherapies for cancer. Its lead candidate, CONV01-α, is a PSMA-targeted monoclonal antibody linked to the alpha-emitting radioisotope actinium-225, designed to deliver tumor-killing radiation to metastatic castration-resistant prostate cancer while sparing healthy tissue. The technology, pioneered in the lab of PSMA-targeting pioneer Dr. Neil Bander and licensed from Cornell University, is led by oncologist Dr. Philip Kantoff.
Philip Kantoff
Philip Kantoff is a medical oncologist who spent three decades shaping how the world treats prostate cancer, then walked away from running medicine at one of the country's largest cancer hospitals to start a company. As co-founder and CEO of Convergent Therapeutics in Cambridge, Massachusetts, he is developing CONV01-alpha, an alpha-emitting radioantibody that hunts down prostate tumor cells and irradiates them at close range. He has published more than 500 papers, been cited over 85,000 times, mentored a generation of oncology leaders, and at an age when most peers retire, raised $90 million in Series A funding to bring a new class of cancer therapy into the clinic.